Dublin - Research and Markets (http://www.researchandmarkets.com/research/6cbcb394/turkey_pharmaceuti) has announced the addition of the "Turkey Pharmaceuticals and Healthcare Report Q2 2012" report to their offering.
BMI View:
While the Turkish pharmaceutical industry has achieved some concessions following additional price cuts and public discounts announced in November 2011, the impact of the November decree remains negative. That aside, BMI emphasises that the number-one concern for drugmakers in 2012 should be lira weakness. BMI's Country Risk team have further revised down our expectations for the lira in 2012.
With publicly purchased drug prices tied to a historic lira/euro exchange rate, there is no way drugmakers can raise prices to offset the weakness of the local currency and ensure stable repatriated revenues. This means global drugmakers in Turkey are completely exposed to lira weakness and this will add to the list of challenges already faced by the industry.
Key Trends And Developments:
.. In mid-November 2011, BMI downgraded its 2012 growth expectations for Turkey's pharmaceutical market on the back of fresh price cuts and public discounts announced by the government.
.. In December 2011, the Social Security Institution (SGK) announced concessions that affect about 350 types of drugs and produced two lists of products that have been changed. s.
.. The continued weakness of the Turkish lira is the primary concern for multinational drugmakers operating in the country. The fact that this issue still fails to be addressed in the latest decree and subsequent compromises will be another irritation for foreign firms.
About This Report:
Business Monitor International's Turkey Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Turkey's pharmaceuticals and healthcare industry.
Key Topics Covered:
- Executive Summary
- SWOT Analysis
- Pharmaceuticals & Healthcare Risk/Reward Ratings
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Turkey Demographic Data
- BMI Methodology
Companies Mentioned
- Abdi Ibrahim
- Eczacibasi Pharmaceuticals
- Sanovel Pharmaceuticals
- Deva (EastPharma)
- Fako (Actavis)
- Mustafa Nevzat Ilac Sanayi (MN) Pharmaceuticals
- Novartis
- Pfizer
- Sanofi
- GlaxoSmithKline
- Roche
- AstraZeneca
- Bayer
- Merck & Co
For more information visit http://www.researchandmarkets.com/research/6cbcb394/turkey_pharmaceuti